Why Selecta Biosciences Tumbled 34% Today

Why Selecta Biosciences Tumbled 34% Today

What happened After the company reported its gout drug, SEL-212, failed to meet its primary endpoint in a mid-stage clinical trial, shares in Selecta Biosciences (NASDAQ: SELB) traded 33.5% lower on Thursday.